Study S000013

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Participants With Mild to Moderate Hypertension Complicated by Overweight/Obesity Who Have Not Received Antihypertensive Drug Treatment

ClinicalTrials.gov record

Registration

Registration: NCT07469800
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 336
Start: 2026-04-23
Primary completion: 2026-08-01
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Overweight; Obesity; Hypertensive
Interventions: DRUG:IBI362; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment. [Week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.